242 related articles for article (PubMed ID: 31696669)
1. Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism?
Awouters M; Vanderschueren D; Antonio L
Andrology; 2020 Nov; 8(6):1590-1597. PubMed ID: 31696669
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review.
Raheem OA; Chen T; Akula KP; Greenberg J; Le TV; Chernobylsky D; Sikka SC; Walsh TJ
Sex Med Rev; 2021 Jul; 9(3):381-392. PubMed ID: 33933392
[TBL] [Abstract][Full Text] [Related]
3. Effect of oestrogen modulation on semen parameters in men with secondary hypogonadism: Systematic review and meta-analysis.
de Silva NL; Dissanayake H; Suarez C; Wickramarachchi RE; Ramasamy R; Dhillo WS; Minhas S; Corona G; Jayasena CN
Andrology; 2024 Feb; 12(2):259-276. PubMed ID: 37306109
[TBL] [Abstract][Full Text] [Related]
4. Novel androgen therapies including selective androgen receptor modulators.
Kang J; Chen R; Tharakan T; Minhas S
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101686. PubMed ID: 35981955
[TBL] [Abstract][Full Text] [Related]
5. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
6. EAA clinical practice guidelines-gynecomastia evaluation and management.
Kanakis GA; Nordkap L; Bang AK; Calogero AE; Bártfai G; Corona G; Forti G; Toppari J; Goulis DG; Jørgensen N
Andrology; 2019 Nov; 7(6):778-793. PubMed ID: 31099174
[TBL] [Abstract][Full Text] [Related]
7. "Cherchez La Femme": Modulation of Estrogen Receptor Function With Selective Modulators: Clinical Implications in the Field of Urology.
Helo S; Wynia B; McCullough A
Sex Med Rev; 2017 Jul; 5(3):365-386. PubMed ID: 28372959
[TBL] [Abstract][Full Text] [Related]
8. Hypergonadotropic Hypogonadism: Management of Infertility.
Kalkanli A; Akdere H; Cevik G; Salabas E; Cilesiz NC; Kadioglu A
Curr Pharm Des; 2021; 27(24):2790-2795. PubMed ID: 33138760
[TBL] [Abstract][Full Text] [Related]
9. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Grouthier V; Lebrun-Vignes B; Glazer AM; Touraine P; Funck-Brentano C; Pariente A; Courtillot C; Bachelot A; Roden DM; Moslehi JJ; Salem JE
Heart; 2018 Nov; 104(22):1859-1863. PubMed ID: 29720397
[TBL] [Abstract][Full Text] [Related]
10. Late-onset Hypogonadism: Bone health.
Rochira V
Andrology; 2020 Nov; 8(6):1539-1550. PubMed ID: 32469467
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy.
Ide V; Vanderschueren D; Antonio L
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375030
[TBL] [Abstract][Full Text] [Related]
12. Alternatives to Testosterone Therapy: A Review.
Lo EM; Rodriguez KM; Pastuszak AW; Khera M
Sex Med Rev; 2018 Jan; 6(1):106-113. PubMed ID: 29174957
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of adverse events of endocrine therapies among older patients with breast cancer.
Honma N; Makita M; Saji S; Mikami T; Ogata H; Horii R; Akiyama F; Iwase T; Ohno S
Support Care Cancer; 2019 Oct; 27(10):3813-3822. PubMed ID: 30729298
[TBL] [Abstract][Full Text] [Related]
14. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Robertson JFR; Paridaens RJ; Lichfield J; Bradbury I; Campbell C
Eur J Cancer; 2021 Mar; 145():19-28. PubMed ID: 33418233
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy.
Barbonetti A; D'Andrea S; Francavilla S
Andrology; 2020 Nov; 8(6):1551-1566. PubMed ID: 32068334
[TBL] [Abstract][Full Text] [Related]
16. Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review.
Nightingale TE; Moore P; Harman J; Khalil R; Gill RS; Castillo T; Adler RA; Gorgey AS
J Spinal Cord Med; 2018 Nov; 41(6):624-636. PubMed ID: 28770686
[TBL] [Abstract][Full Text] [Related]
17. Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects.
Colleluori G; Chen R; Turin CG; Vigevano F; Qualls C; Johnson B; Mediwala S; Villareal DT; Armamento-Villareal R
Front Endocrinol (Lausanne); 2020; 11():277. PubMed ID: 32499757
[No Abstract] [Full Text] [Related]
18. Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.
Tienforti D; Castellini C; Di Giulio F; Totaro M; Dalmazio G; Spagnolo L; Muselli M; Corona G; Baroni MG; Barbonetti A
Andrology; 2023 Sep; 11(6):1067-1076. PubMed ID: 36604313
[TBL] [Abstract][Full Text] [Related]
19. Testosterone Therapy: What We Have Learned From Trials.
Corona G; Torres LO; Maggi M
J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
[TBL] [Abstract][Full Text] [Related]
20. Novel Therapy for Male Hypogonadism.
Carrasquillo R; Chu K; Ramasamy R
Curr Urol Rep; 2018 Jun; 19(8):63. PubMed ID: 29886559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
